Your browser doesn't support javascript.
loading
Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.
Santos, Florinda A; Reis, Rui Manuel; Barroti, Lucas C; Pereira, Allan A L; Matsushita, Marcus M; de Carvalho, Ana Carolina; Datorre, José Guilherme; Berardinelli, Gustavo N; Araujo, Raphael L C.
Afiliação
  • Santos FA; Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil.
  • Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • Barroti LC; Life and Health Sciences Research Institute (ICVS), School Medicine, University of Minho, Braga, Portugal.
  • Pereira AAL; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimaraes, Portugal.
  • Matsushita MM; Department of Dermatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
  • de Carvalho AC; Clinical Oncology Department, Hospital Sirio Libanes de Brasilia-DF, Sao Paulo, Brazil.
  • Datorre JG; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
  • Berardinelli GN; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
  • Araujo RLC; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
J Gastrointest Cancer ; 2023 Aug 23.
Article em En | MEDLINE | ID: mdl-37608030
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article